Ligand efficiency metrics: Why all the fuss?

Future Medicinal Chemistry

Volumn 7, Issue 11, 2015, Pages 1363-1365

  Reynolds, Charles H ^a  

^a Quant Engineering   (United States)

Author keywords

drug discovery metrics; fit quality; ligand efficiency; lipophilic ligand efficiency

Indexed keywords

LIGAND; PROTEIN; PROTEIN BINDING;

BINDING SITE; DRUG RESEARCH; LIGAND EFFICIENCY; LIPOPHILICITY; MEDICINAL CHEMISTRY; MOLECULAR SIZE; PARAMETERS; PRIORITY JOURNAL; REVIEW; DRUG DEVELOPMENT; HUMAN; METABOLISM; PROCEDURES;

DRUG DISCOVERY; HUMANS; LIGANDS; PROTEIN BINDING; PROTEINS;

EID: 84938514887     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.70     Document Type: Review

References (18)

1. Kuntz ID, Chen K, Sharp KA, Kollman PA. The maximal affnity of ligands. Proc. Natl Acad. Sci. USA 96 (18), 9997-10002 (1999).
2. Hopkins Andrew L, Groom Colin R, Alex A. Ligand effciency: a useful metric for lead selection. Drug Discov. Today 9(10), 430-431 (2004).
3. Lipinski CA. Lead-and drug-like compounds: the rule-of-five revolution. Drug Discov. Today Technol. 1(4), 337-341 (2004).
4. Rees DC, Congreve M, Murray CW, Carr R. Fragment-based lead discovery. Nat. Rev. Drug Discov. 3(8), 660-672 (2004).
5. Rishton GM. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov. Today 8(2), 86-96 (2003).
6. Hopkins AL, Keseru GM, Leeson PD, Rees DC, Reynolds CH. The role of ligand effciency metrics in drug discovery. Nat. Rev. Drug Discov. 13(2), 105-121 (2014).
7. Kenny P, Leitão A, Montanari C. Ligand effciency metrics considered harmful. J. Comput. Aided Mol. Des. 28(7) 699-710 (2014).
8. Shultz MD. Improving the plausibility of success with ineffcient metrics. ACS Med. Chem. Lett. 5(1), 2-5 (2013).
9. Ligand effciency: a response to Shultz. http://pipeline.corante.com
10. Erlanson, D. In defense of ligand effciency-and poll. http://practicalfragments.blogspot.com
11. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6(11) 881-890 (2007).
12. Reynolds CH, Tounge BA, Bembenek SD. Ligand binding effciency: trends, physical basis, and implications. J. Med. Chem. 51(8), 2432-2438 (2008).
13. Murray C W, Erlanson DA, Hopkins AL et al. Validity of ligand effciency metrics. ACS Med. Chem. Lett. 5(6), 616-618 (2014).
14. Vieth M, Sutherland JJ. Dependence of molecular properties on proteomic family for marketed oral drugs. J. Med. Chem. 49, 3451-3453 (2006).
15. Nissink JW. Simple size-independent measure of ligand ef fcienc y. J. Chem. Inf. Model. 49 (6), 1617-1622 (2009).
16. Zhu T, Cao S, Su P-C et al. Hit identifcation and optimization in virtual screening: practical recommendations based on a critical literature analysis: miniperspective. J. Med. Chem. 56(17), 6560-6572 (2013).
17. Stamford AW, Scott JD, Li SW et al. Discovery of an orally available, brain penetrant BACE1 inhibitor that affords robust CNS abeta reduction. ACS Med. Chem. Lett. 3(11), 897-902 (2012).
18. Perola E. An analysis of the binding effciencies of drugs and their leads in successful drug discovery programs. J. Med. Chem. 53(7), 2986-2997 (2010).